Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joyzyme GroupHKSE:08622 +3.13%40 Quick Ratio is 3.66 as of Dec. 2025, which is 25% below its 10-year median of 4.90. GuruFocus rates HKSE:08622 with a GF Score™ of 40/100 and a GF Value™ of HK$0.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Joyzyme Group ranks better than 82.61% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Joyzyme Group's quick ratio for the quarter that ended in Dec. 2025 was 3.66.
Joyzyme Group has a quick ratio of 3.66. It generally indicates good short-term financial strength.
The historical rank and industry rank for Joyzyme Group's Quick Ratio or its related term are showing as below:
HKSE:08622'
s Quick Ratio Range Over the Past 10 Years
Min: 2.17 Med: 4.9 Max: 8.43
Current: 3.66
During the past 11 years, Joyzyme Group's highest Quick Ratio was 8.43. The lowest was 2.17. And the median was 4.90.
HKSE:08622's Quick Ratio is ranked better than 82.61% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.42
vs HKSE:08622: 3.66
Joyzyme Group (HKSE:08622) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Joyzyme Group Quick Ratio Related Terms
Joyzyme Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Joyzyme Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Joyzyme Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joyzyme Group Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joyzyme Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Joyzyme Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Joyzyme Group's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joyzyme Group (HKSE:08622) has a Quick Ratio of 3.66 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Joyzyme Group and its competitors. This is 25% below median its historical median of 4.90. Over the past decade, Joyzyme Group's Quick Ratio has ranged from 2.17 to 8.43. According to the industry distribution chart, Joyzyme Group ranks #173 out of 995 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Joyzyme Group's Quick Ratio too high?
Joyzyme Group's current Quick Ratio of 3.66 is 25% below median its 10-year median of 4.90. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 8.43. The Drug Manufacturers industry median Quick Ratio is 1.42. Joyzyme Group's value of 3.66 is 157.7% above this industry median. Based on the distribution chart, Joyzyme Group ranks #173 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Joyzyme Group has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joyzyme Group's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joyzyme Group ranks #173 out of 995 companies for Quick Ratio. This places Joyzyme Group in the top 17% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.42. Joyzyme Group's value of 3.66 is 157.7% above this benchmark. Historically, Joyzyme Group's own Quick Ratio has ranged from 2.17 to 8.43 over the past decade. While the company's 10-year median is 4.90 vs. the industry median of 1.42, Joyzyme Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.42, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joyzyme Group's current Quick Ratio of 3.66 is 157.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Joyzyme Group and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joyzyme Group's current Quick Ratio is 3.66, which is 25% below median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joyzyme Group stock overvalued right now?
Based on GuruFocus' analysis, Joyzyme Group (HKSE:08622) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.17, compared to a current price of HK$0.17 — trading 2.9% below its estimated fair value. The current Quick Ratio is 3.66, which is 25% below median its 10-year median of 4.90 and 157.7% above the Drug Manufacturers industry median of 1.42. Joyzyme Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Joyzyme Group (HKSE:08622), the current Quick Ratio is 3.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joyzyme Group (HKSE:08622) Overvalued in 2026?
Based on GuruFocus' analysis, Joyzyme Group stock appears to be undervalued.
The current stock price of HK$0.17 is trading 2.9% below its estimated GF Value™ of HK$0.17.
GuruFocus considers Joyzyme Group to be Fairly Valued.
Key valuation signals for HKSE:08622:
Quick Ratio: 3.66 (25% below median its 10-year median of 4.90)
GF Value™: HK$0.17 vs. price of HK$0.17 (2.9% below fair value)
Industry Position: 157.7% above the Drug Manufacturers median (#173 of 995)
No single metric tells the full story. See the HKSE:08622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Joyzyme Group Ltd is an investment holding company. The Company and its subsidiaries are principally engaged in research and development, manufacture, marketing, and sale of biological reagents and auxiliary reproductive supplies and equipment, and healthcare products and supplements in the People's Republic of China (the PRC). It operates in two segments: Biological reagents and auxiliary reproductive supplies and equipment, and Healthcare products and supplements. It generates the majority of its revenue from the biological reagents and auxiliary reproductive supplies and equipment segment. Geographically, it generates revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:08622
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08622 has been successfully added to your 
